Broker’s call: Asian Paints (Sell)

Target: ₹2,570

Target: ₹2,570

CMP: ₹2,878.90

Asian Paints’ net sales declined 0.6 per cent y-o-y (5 per cent growth estimated) in Q4, as the domestic decorative coatings business decelerated 1.8 per cent, hit by price cuts, higher discounts and downtrading (volumes grew by 10 per cent).

In Q4, urban areas drove growth with double-digit volume increase, while rural areas saw slightly slower growth. The economy segment grew on the back of consumers downtrading from the premium segment. But the luxury segment witnessed notable traction in Q4. The waterproofing segment experienced significant growth, supported by the projects business. New product launches contributed 11 per cent to FY24 sales. Auto coatings and general industrial coatings exhibited stronger growth of 10 per cent and 8 per cent, respectively, buoyed by robust performances in auto OEM coatings and protective and powder coatings.

APNT foresees double-digit volume growth to continue given the rural pickup in Q1FY25. With the recent launch of Neo Bharat latex paint, a product strategically aimed to tap the vast distemper and low-cost emulsion market valued at ₹5,000 crore, APNT is poised to fuel growth in the economy segment.

Going forward, value growth is projected to trail volume growth by 5-6 per cent, even as APNT anticipates a slower pace of downtrading in FY25.

Like (0)
Previous May 14, 2024 4:15 pm
Next May 14, 2024 4:16 pm

Related posts

  • Multi-maturity U.S. Treasury yields rise rapidly

    The convergence of interest rate cut expectations is rewriting the narrative of global capital markets. Recently, due to the impact of U.S. economic fundamentals such as inflation and employment that exceeded expectations, market expectations for the Federal Reserve to cut interest rates within the year have declined. The “anchor of global asset pricing” has made waves again. The 10-year U.S. Treasury yield recently broke through the 4.5% mark and remains above this point. Some market participants are worried that the “nightmare” of 10-year U.S. bond yields pointing to 5% may strike again. Analysts believe that the current asset prices are more reflected in the correction of front-running transactions in anticipation of interest rate cuts. Looking ahead, interest rate cut expectations may continue to swing driven by data and geopolitics, affecting the trend of U.S. bond yields. Multi-maturity U.S. Treasury yields rise The rapid rise in U.S. bond yields has once again attracted market attention. On April 10, local time, as the U.S. Consumer Price Index (CPI) in March exceeded expectations across the board, the market was worried about the prospect…

    stock options April 15, 2024
  • Shanxi Fenjiu\’s mid-to-high-priced alcohol revenue in 2023 will be 23.203 billion yuan, a year-on-year increase of 22.56%, with a gross profit margin of 84.09%

    Special topic: Shanxi Fenjiu releases 2023 annual report, jumping to 30 billion annual revenue level On the evening of April 25, Shanxi Fenjiu released the company\’s 2023 annual report. The annual report shows that in 2023, the company achieved operating income of 31.928 billion yuan, a year-on-year increase of 21.8%; net profit attributable to listed companies was 10.438 billion yuan, a year-on-year increase of 28.93%. Shanxi Fenjiu divides its alcohol revenue into medium and high-priced alcoholic beverages and other alcoholic beverages. The former refers to products priced at 130 yuan per liter and above. Representative products include the Blue and White Fenjiu series, Panama Fenjiu series, Laobai Fenjiu series, Qingxiang Zhuyeqing series, etc. Representative products of the latter include the Ordinary Fenjiu Series, Ordinary Bamboo Leaf Green Series, Xinghuacun Liquor Series, etc. Specifically, mid- to high-priced alcoholic beverages will achieve revenue of 23.203 billion yuan in 2023, a year-on-year increase of 22.56%. The gross profit margin was 84.09%, an increase of 0.11 percentage points over the previous year. Other alcoholic beverages achieved operating income of 8.540 billion yuan, a year-on-year…

    stock options April 25, 2024
  • British opioid withdrawal drug maker Indivior confirms relocation of primary launch site to New York

    The British drugmaker, which makes opioid addiction treatments Suboxone and Sublocade, said shareholders had expressed support for the move, which would retain London as a secondary listing location for Indivior.

    stock options April 25, 2024
  • Nanda Optoelectronics: Net profit in the first quarter of 2024 was 82.1105 million yuan, a year-on-year increase of 9.52%

    CSI Intelligent Financial News Nanda Optoelectronics (300346) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 509 million yuan, a year-on-year increase of 27.88%; net profit attributable to the parent company was 82.1105 million yuan, a year-on-year increase of 9.52%; non-net profit after deducting 61.5303 million yuan, a year-on-year increase of 14.40%; generated from operating activities Net cash flow was -21.4457 million yuan, compared with 8.4528 million yuan in the same period last year; during the reporting period, Nanda Optoelectronics\’ basic earnings per share was 0.15 yuan, and the weighted average return on net assets was 3.63%.

    stock options April 25, 2024
  • Jingneng Clean Energy (00579.HK) appoints Chen Dayu as chairman of the board of directors

    Gelonghui April 25丨Jingneng Clean Energy (00579.HK) announced that Mr. Zhang Fengyang has resigned as executive director, chairman of the board of directors, chairman of the strategy committee of the board of directors due to job changes and in accordance with Article 3.05 of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited The positions of authorized representatives of the following companies will be effective from April 25, 2024.

    stock options April 25, 2024
  • Belstar Microfinance plans IPO to raise ₹1,300 crore

    Belstar Microfinance Ltd, a subsidiary of Muthoot Finance, has filed a DRHP with SEBI to raise ₹1,300 crore. The company plans to raise the funds through IPO of equity shares with a face value ₹10 each.

    stock options May 7, 2024